Research programme: Zika virus vaccine - CEVEC Pharmaceuticals/NewLink Genetics

Drug Profile

Research programme: Zika virus vaccine - CEVEC Pharmaceuticals/NewLink Genetics

Latest Information Update: 22 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CEVEC Pharmaceuticals; NewLink Genetics Corporation
  • Class Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Zika virus infection

Most Recent Events

  • 09 Feb 2017 NewLink Genetics licenses CAP® technologies from CEVEC Pharmaceuticals
  • 09 Feb 2017 Early research in Zika virus infection (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top